Voyager Therapeutics Price to Book Ratio 2014-2022 | VYGR
Historical price to book ratio values for Voyager Therapeutics (VYGR) over the last 10 years. The current price to book ratio for Voyager Therapeutics as of July 01, 2022 is 3.08.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Voyager Therapeutics Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2022-07-01 |
6.08 |
|
3.06 |
| 2022-03-31 |
7.62 |
$1.99 |
3.84 |
| 2021-12-31 |
2.71 |
$2.51 |
1.08 |
| 2021-09-30 |
2.63 |
$2.31 |
1.14 |
| 2021-06-30 |
4.13 |
$2.93 |
1.41 |
| 2021-03-31 |
4.71 |
$3.63 |
1.30 |
| 2020-12-31 |
7.15 |
$4.13 |
1.73 |
| 2020-09-30 |
10.67 |
$4.46 |
2.39 |
| 2020-06-30 |
12.62 |
$2.07 |
6.11 |
| 2020-03-31 |
9.15 |
$2.16 |
4.24 |
| 2019-12-31 |
13.95 |
$2.70 |
5.17 |
| 2019-09-30 |
17.21 |
$2.94 |
5.86 |
| 2019-06-30 |
27.22 |
$3.23 |
8.43 |
| 2019-03-31 |
19.14 |
$2.75 |
6.95 |
| 2018-12-31 |
9.40 |
$1.44 |
6.55 |
| 2018-09-30 |
18.92 |
$2.03 |
9.32 |
| 2018-06-30 |
19.54 |
$2.56 |
7.64 |
| 2018-03-31 |
18.79 |
$3.08 |
6.10 |
| 2017-12-31 |
16.60 |
$4.25 |
3.91 |
| 2017-09-30 |
20.59 |
$3.25 |
6.34 |
| 2017-06-30 |
8.96 |
$4.05 |
2.21 |
| 2017-03-31 |
13.24 |
$4.75 |
2.79 |
| 2016-12-31 |
12.74 |
$5.31 |
2.40 |
| 2016-09-30 |
12.01 |
$5.87 |
2.05 |
| 2016-06-30 |
10.99 |
$6.16 |
1.78 |
| 2016-03-31 |
8.73 |
$6.51 |
1.34 |
| 2015-12-31 |
21.90 |
$6.78 |
3.23 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.234B |
$0.037B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
